News Column

PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

July 3, 2014



GHENT, Belgium, July 3, 2014 (GLOBE NEWSWIRE) -- Ablynx[Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO") took place today and as a result, Ablynx issued 4,908,332 new shares.

Ablynx NV also publishes the following information in accordance with article 15 of the Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the "Transparency Law"):

Total amount of the share capital: €100,911,165.12
Total number of securities carrying voting rights: 53,991,659
Total number of voting rights (denominator): 53,991,659

Ablynx NV has in total 3,178,511 outstanding warrants, of which 904,000 warrants give the holder the right to a total of 452,000 shares (two warrants giving the right to subscribe to one share) and of which 2,274,511 warrants give the holder the right to a total of 2,274,511 shares (one warrant giving the right to subscribe to one share). The acceptance and issuing of 725,000 warrants (one warrant giving the right to subscribe to one share), which was decided upon in principle by the extraordinary general meeting of Ablynx of 24 April 2014, is currently pending. The total number of voting rights, which can be acquired as a result of the exercise of the outstanding warrants, amounts to 2,726,511 (without taking into account the pending 725,000 warrants).

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has more than 30 programmes in the pipeline and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses

CEO

t:   +32 (0)9 262 00 07

m: +44 (0)7771 954 193 /

     +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com

Marieke Vermeersch

Associate Director Investor Relations

t:   +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e:  marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville

t:   +44 203 709 5700

e:  ablynx@consilium-comms.com

pdf format of the press release http://hugin.info/137912/R/1813470/626686.pdf

HUG#1813470

Source: Ablynx


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: GlobeNewswire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters